PubMed
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence
Anisimov VN, Khavinson VK, Popovich IG, et al. Biogerontology. 2003
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 35 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 18% · Mixed 2% · Unfavorable overall 80%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2–3 mg · Most common: 5+ mg
Reports span 0.01 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 56% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 44 days · Based on 45 repeat reporters
Published sources linked on the Epithalon and MOTS-c wiki pages.
PubMed
Anisimov VN, Khavinson VK, Popovich IG, et al. Biogerontology. 2003
PubMed
Khavinson VK, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003
PubMed
Khavinson VK. Bull Exp Biol Med. 2002
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Khavinson VKh, Bondarev IE, Butyugov AA, et al. Bulletin of experimental biology and medicine. 2004
PubMed
Khavinson VK, Yakovleva ND, Popuchiev VV, et al. Bull Exp Biol Med. 2001
PubMed
Khavinson VKh, Kvetnoi IM, Popuchiev VV, et al. Arkh Patol. 2001
PubMed
Khavinson VK, Konovalov SS, Yuzhakov VV, et al. Bull Exp Biol Med. 2001
PubMed
Khavinson VKh, Golubev AG. Adv Gerontol. 2002
PubMed
Khavinson V, Razumovsky M, Trofimova S, et al. Neuro Endocrinol Lett. 2002
Review Article
Khavinson VKh. Neuro Endocrinol Lett. 2002
PubMed
Khavinson V, Diomede F, Mironova E, et al. Molecules. 2020
Review Article
Rahman OF, Lee SJ, Seeds WA. J Am Acad Orthop Surg Glob Res Rev. 2026
PubMed
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015
PubMed
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021
PubMed
Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023
PubMed
Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016